Please use this identifier to cite or link to this item:
|Title:||Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo|
|Other Titles:||Measures of DNA damage sensitivity are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo|
|Authors:||Bowman, Karen J.|
Al-Moneef, Manar M.
Sherwood, Benedict T.
Colquhoun, Alexandra J.
Goddard, Jonathan C.
Griffiths, T.R. Leyshon
Butterworth, Paul C.
Khan, Masood A
Summerton, Duncan J.
Steward, William P.
McKelvey-Martin, Valerie J.
McKeown, Stephanie R.
Kockelbergh, Roger C.
Mellon, J. Kilian
Symonds, R. Paul
Jones, George D.D.
|Publisher:||Wiley-Blackwell for the International Union against Cancer (UICC)|
|Citation:||International Journal of Cancer, 2013, in press|
|Abstract:||Bladder cancer patients suffer significant treatment failure, including high rates of recurrence and poor outcomes for advanced disease. If mechanisms to improve tumour cell treatment sensitivity could be identified and/or if tumour response could be predicted, it should be possible to improve local-control and survival. Previously, we have shown that radiation-induced DNA damage, measured by alkaline Comet assay (ACA), correlates bladder cancer cell radiosensitivity in vitro. In the present study we firstly show that modified-ACA measures of cisplatin and mitomycin-C-induced damage also correlate bladder cancer cell chemosensitivity in vitro, with essentially the same rank order for chemosensitivity as for radiosensitivity. Furthermore, ACA studies of radiation-induced damage in different cell-DNA substrates (nuclei, nucleoids & intact parent cells) suggest that it is a feature retained in the prepared nucleoids that is responsible for the relative damage sensitivity of bladder cancer cells, suggestive of differences in the organisation of DNA within resistant vs. sensitive cells. Secondly, we show that ACA analysis of biopsies from bladder tumours reveal that reduced DNA damage sensitivity associates with poorer treatment outcomes, notably that tumours with a reduced damage response show a significant association with local recurrence of non-invasive disease and that reduced damage response was a better predictor of recurrence than the presence of high-risk histology in this cohort. In conclusion, this study demonstrates that mechanisms governing treatment-induced DNA damage are both central to and predictive of bladder cancer cell treatment sensitivity and exemplifies a link between DNA damage resistance and both treatment response and tumour aggression.|
|Rights:||Copyright © 2013 UICC. Deposited with reference to the publisher’s archiving policy available on the SHERPA/RoMEO website.|
|Description:||This is the pre-peer reviewed version of the following article: Bowman, K.J., Al-Moneef, M.M. et al. ‘Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo’ in International Journal of Cancer, 2013 (in press), which has been published in final form at http://dx.doi.org/ 10.1002/ijc.28437.|
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Files in This Item:
|Comet assay measures pre-print.pdf||Pre-review (submitted draft)||789.95 kB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.